BIONET Corp. (TPEX:1784)

Market Cap	4.60B +10.3%
Revenue (ttm)	1.22B +3.8%
Net Income	69.82M +25.3%
EPS	1.38 +24.9%
Shares Out	50.31M
PE Ratio	66.19
Forward PE	n/a
Dividend	1.42 (1.55%)
Ex-Dividend Date	Oct 3, 2025

Volume	440,061
Average Volume	363,654
Open	95.30
Previous Close	95.40
Day's Range	91.40 - 95.30
52-Week Range	62.40 - 118.00
Beta	0.47
RSI	36.11
Earnings Date	Mar 17, 2026

About BIONET

BIONET Corp. engages in the cell therapy business in Taiwan and internationally. The company offers stem cell banking services, such as stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and PBSC and immune cells; and genetic testing services. It also provides storage and application of hematopoietic stem cells; regenerative medicine, analytical testing, clinical and preclinical research, and commercialized cell-derived products; and Exosome, a cell-free therapy. The company was founded in 1989 and is...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1989
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 1784

Financial Performance

In 2024, BIONET's revenue was 1.22 billion, an increase of 8.40% compared to the previous year's 1.13 billion. Earnings were 83.70 million, an increase of 6.76%.